George Somlo, M.D.

  • Director, Pharmaceutical Initiatives
  • Professor, Departments of Medical Oncology & Therapeutics Research and Hematology & Hematopoietic Cell Transplantation
  • Medical Oncologist and Hematologist

George Somlo, M.D.

Clinical Specialties
  • Medical Oncology
Areas of Expertise
  • Breast oncology (advanced and inflammatory breast cancer, triple negative and HER2+ and other subtypes)
  • Multiple myeloma
  • Hematology and Hematopoietic Cell Transplantation
Research Focus
  • Triple-negative breast cancer
  • Developmental Cancer Therapeutics Program
  • Phase 2 HER2-targeting
  • Multiple myeloma phase 1-3 trials
  • Stem cell transplantation trials
Other Languages Spoken
  • Hungarian

George Somlo, M.D., is an internationally known breast cancer and hematology researcher at City of Hope, and director of pharmaceutical initiatives at the institution.

Dr. Somlo is currently professor with joint appointments in the departments of Medical Oncology & Therapeutics Research and Hematology & Hematopoietic Cell Transplantation. Among his many institutional functions, he is president of the medical staff and a member of the City of Hope board of directors. Dr. Somlo served as director of breast oncology, co-director of the Breast Cancer Program and director of the Multiple Myeloma Program.

Dr. Somlo’s clinical/translational research interests extend beyond a single discipline. He is a longtime panel member of the National Comprehensive Cancer Netwrok breast cancer and multiple myeloma guideline committees. He has been actively participating in a variety of ASCO committees focusing on breast cancer, and has been involved with guideline development for growth factors. He is a Multiple Myeloma Steering Committee member in the BMT-Clinical Trial Network.

Dr. Somlo has been a member of grant review panels (Department of Defense, National Comprehensive Cancer Network, Susan G. Komen, National Cancer Institute of the Netherlands and Singapore), and reviewer of many prestigious journals including the New England Journal of Medicine, Journal of the American Medication Association, Clinical Cancer Research, Lancet Oncology, Journal of Clinical Oncology and many others.

Areas of his funded active research include identifying molecular targets and profiles responsible for resistance in breast cancer, whether in primary or metastatic, or circulating tumor cell “compartments” in patients with locally advanced/inflammatory and Stage 4 breast cancer. 

Dr. Somlo is particularly interested in collaborations focusing on triple-negative breast cancer and overcoming breast cancer stem cell resistance in the preclinical and subsequently clinical settings. He is co-leader for the Breast Cancer Program of the National Cancer Institute-contract-supported California Cancer Center Consortium , a member of the leadership team in the SWOG Breast Committee, and principal or co-principal investigator for trials ranging from institutional phase 2 HER2-targeting and triple-negative breast cancer-focused neoadjuvant studies and co-leading a PARP-inhibitor trial in BRCA carriers in the National Cancer Institute-contracted California Cancer Consortium. He is the principal investigator of a phase 3 SWOG cooperative group trial aimed to define better therapies for patients with Stage 4 hormone-receptor positive breast cancer. 

Dr. Somlo is also actively involved as principal or co-principal investigator in institutional, cooperative group and industry-sponsored phase 1-3 trials in multiple myeloma, co-chairing a national trial focusing on the role of single vs. tandem autologous stem cell transplantation and novel regimens. He is leading an institutional trial incorporating total marrow irradiation into a transplant regimen, and testing novel — including immunotherapeutic — agents.

Dr. Somlo is a cum laude graduate of the University of Semmelweis Medical School in Budapest, Hungary. He completed his fellowship at the Department of Virus-Vaccine Control at the National Institute of Public Health and after a short stay in the Department of Head and Neck Surgery at the National Cancer Institute in Budapest, he moved to California. Following internal medicine training in the University of California, Irvine-Long Beach VA program, he completed fellowship training in medical oncology, hematology and bone marrow transplantation at City of Hope. 

Dr. Somlo has published over 200 peer-reviewed papers and book chapters, and is funded by the National Institutes of Health and Department of Defense, and was prior recipient of SWOG-Hope Foundation.


  • 1972 -1978, University of Semmelweis Medical School, Budapest, Hungary, M.D., F.A.C.P.


  • 1985 -1988, Fellow, Medical Oncology, Department of Medical Oncology & Therapeutics Research and Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA


  • 1982 -1985, University of California, Irvine and Long Beach, VAMC, Internship and Residency in Internal Medicine.


  • 1982 -1985, University of California, Irvine and Long Beach, VAMC, Internship and Residency in Internal Medicine.

Information listed here is obtained from Pubmed, a public database; City of Hope is not responsible for its accuracy. Click here for a complete listing.

  • 2017 Forbes Physician Honor Roll - one of 27 breast oncologists in the U.S. recognized by Forbes as an exemplary physician in the field of oncology
Back To Top